Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC)

被引：0

作者：

Galle, P. R. ^{[1
]}

Crysler, O., V ^{[2
]}

Yarchoan, M. ^{[3
]}

Furuse, J. ^{[4
]}

Sukeepaisarnjaroen, W. ^{[5
]}

Thinh, N. T. ^{[6
]}

Masi, G. ^{[7
]}

Lim, H. Y. ^{[8
]}

Varela, M. ^{[9
]}

Gupta, C. ^{[10
]}

Makowsky, M. ^{[11
]}

Negro, A. ^{[11
]}

Abou-Alfa, G. K. ^{[12
,13
]}

机构：

[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Mainz, Germany

[2] Univ Michigan, Ann Arbor, MI USA

[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[4] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[5] Khon Kaen Univ, Khon Kaen, Thailand

[6] 108 Cent Mil Hosp, Hanoi, Vietnam

[7] Pisa Univ, Pisa, Italy

[8] Sungkyunkwan Univ, Seoul, South Korea

[9] Univ Oviedo, IUOPA, ISPA, FINBA, Oviedo, Spain

[10] AstraZeneca, Wilmington, DE USA

[11] AstraZeneca, Gaithersburg, MD USA

[12] Cornell Univ, New York, NY USA

[13] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V899

引用

页码：129 / 129

页数：1

共 50 条

[1] Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
Crysler, Oxana V.
Yarchoan, Mark
Furuse, Junji
Galle, Peter R.
Sukeepaisarnjaroen, Wattana
Nguyen Tien Thinh
Masi, Gianluca
Lim, Ho Yeong
Varela, Maria
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 551 - 551
[2] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, L. S.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S869 - S870
[3] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1466
[4] Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Rimassa, L.
Dayyani, F.
Kelley, R. K.
Sangro, B.
Chan, S. L.
Mccoy, C. L.
Paskow, M. J.
Makowsky, M.
Gupta, C.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S77 - S78
[5] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
[6] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Kudo, M.
Sangro, B.
Kelley, R. K.
Furuse, J.
Park, J-W.
Sunpaweravong, P.
Fasolo, A.
Yau, T.
Kawaoka, T.
Cheng, A-L.
Azevedo, S.
Reig Monzon, M. E.
Assenat, E.
Yarchoan, M.
He, A. R.
Makowsky, M.
Gupta, C.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
[7] Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Monzon, M. E. Reig
Tam, V. C.
Sangro, B.
Archambeaud, I.
Kelley, R. K.
Chan, S. L.
Kudo, M.
Masi, G.
Paskow, M. J.
Makowsky, M.
Gupta, C.
Ran, D.
Negro, A.
Abou-Alfa, G. K.
[J]. ANNALS OF ONCOLOGY, 2024, 35 : S75 - S76
[8] Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Lau, George
Sangro, Bruno
Crysler, Oxana V.
Sukeepaisarnjaroen, Wattana
Lipatov, Oleg
Morimoto, Manabu
Archambeaud, Isabelle
Burgio, Valentina
Phuong, Le Thi Tuyet
Chao, Yee
Peron, Jean-Marie
Berres, Marie-Luise
Ko, Yoo-Joung
Mccoy, Carrie L.
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Lau, George
Cheng, Ann-Lii
Sangro, Bruno
Kudo, Masatoshi
Kelley, Robin Kate
Tak, Won Young
Gasbarrini, Antonio
Reig, Maria
Lim, Ho Yeong
Tougeron, David
De Toni, Enrico N.
Tam, Vincent C.
Mody, Kabir
Gong, Jun
Mccoy, Carrie L.
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Adverse Event Profiles and Time to Onset and Resolution with Tremelimumab ( T) plus Durvalumab (D) in Patients with Unresectable Hepatocellular Carcinoma (uHCC) in the Phase 3 HIMALAYA Trial
De Toni, E. M.
Sangro, B.
Chan, S. L.
Kudo, M.
Kelley, R. K.
-K, Kang Y.
Rimassa, L.
Varela, M.
Dayyani, F.
Makowsky, M.
Marcovitz, M.
Mccoy, C. L.
Negro, A.
Abou-Alfa, G.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 240

← 1 2 3 4 5 →